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ABSTRACT  
In the present work, an attempt has been made to develop immediate release coated tablets of Ritonavir by hot met extrusion method using 16 
station rotary tablet punching machine. The blend of all the formulations showed good flow properties such as bulk density, tapped density. 
The prepared IR coated tablets of ritonavir shown good post compression parameters. They passed all the quality control evalu ation 
parameters as per USP limits. Among all the formulations, F5 formulation showed maximum % drug release i.e., 99 % in 120 mins hence it is 
considered as optimized formulation. The optimized formulation was compared to innovator tablets.  
Keywords: Ritonavir, HPMC, Ethyl cellulose, Copovidone immediate release tablets.  
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1.0. INTRODUCTION  
1.1. Tablets  
Tablets are defined as solid pharmaceutical dosage forms 
containing drug substances with or without suitable diluents 
and prepared either by compression or molding methods. 
Tablets remain popular as a dosage form because of the 
advantages, afforded both to the manufacturer (simplicity & 
economy of preparation, stability and convenience in 
packing, shipping and dispensing). Although tablets are 
more frequently discoid in shape, they also may be round, 
oval, oblong, cylindrical or triangular. They may differ 
greatly in size and weight depending on the amount of drug 
substance present and intended method of administration 
(1). 
1.2. Hot Melt Extrusion Method: 
To date HME has emerged as a novel processing technology 
in developing molecular dispersions of active 
pharmaceutical ingredients (APIs) into various polymer 
or/and lipid matrices which has led this technique to 
demonstrate time controlled, modified, extended, and 
targeted drug delivery. HME has now provided opportunity 
for use of materials in order to mask the bitter taste of active 
substances. Since the industrial application of the extrusion 
process back in the 1930’s, HME has received considerable 
attention from both the pharmaceutical industry and 
academia in a range of applications for pharmaceutical 
dosage forms, such as tablets, capsules, films, and implants 
for drug delivery via oral, transdermal, and transmucosal 
routes (2). This makes HME an excellent alternative to other 
conventionally available techniques such as roll spinning 
and spray drying. In addition to being a proven 
manufacturing process, HME meets the goal of the US Food 
and Drug Administration’s (FDA) process analytical 
technology (PAT) scheme for designing, analyzing, and 
controlling the manufacturing process via quality control 
measurements during active extrusion process. In this 
research work extrusion technique is reviewed based on a 
holistic perspective of its various components, processing 
technologies, and the materials and novel formulation 
design and developments in its varied applications in oral 
drug delivery systems (3). 
1.3. Process Technology of Hot-Melt Extrusion (HME)  
Hot-melt extrusion technique was first invented for the 
manufacturing of lead pipes at the end of the eighteenth 
century. Since then, it has been used in the plastic, rubber, 
and food manufacturing industry to produce items ranging 
from pipes to sheets and bags. With the advent of high 
throughput screening, currently more than half of all plastic 
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products including bags, sheets, and pipes are manufactured 
my HME and therefore various polymers have been used to 
melt and form different shapes for a variety of industrial and 
domestic applications (4). The technology (HME) has proven 
to be a robust method of producing numerous drug delivery 
systems and therefore it has been found to be useful in the 
pharmaceutical industry as well. Extrusion is the process of 
pumping raw materials at elevated controlled temperature 
and pressure through a heated barrel into a product of 
uniform shape and density(5). Breitenbach first introduced 
the development ofmelt extrusion process in pharmaceutical 
manufacturing operations; however, Follonier and his 
coworkers first examined the hot-melt technology to 
manufacture sustained release polymer-based pellets of 
various freely soluble drugs. HME involves the compaction 
and conversion of blends from a powder or a granular mix 
into a product of uniform shape (6). During this process, 
polymers are melted and formed into products of different 
shapes and sizes such as plastic bags, sheets, and pipes by 
forcing polymeric components and active substances 
including any additives or plasticisers through an orifice 
ordie under controlled temperature, pressure, feeding rate, 
and screw speed. 
 However, the theoretical approach to understanding the 
melt extrusion process (Figure 1) can be summarized by 
classifying the whole procedure of HME compaction into the 
following:  
(1) Feeding of the extruder through a hopper, 
(2) Mixing, grinding, reducing the particle size, venting, and 
kneading, 
(3) Flow through the die, and 
(4) Extrusion from the die and further downstream 
processing.
 
 
FIGURE-1 Schematic diagram of the HME process 
 
The extruder generally consists of one or two rotating 
screws (either corotating or counter rotating) inside a 
stationary cylindrical barrel. The barrel is often 
manufactured in sections in order to shorten the residence 
time of molten materials. The sectioned parts of the barrel 
are then bolted or clamped together. An end-plate die is 
connected to the end of the barrel which is determined 
according to the shape of the extruded materials (7). 
1.4. Single-Screw and Twin-Screw Extruder 
A single-screw extruder consists of one rotating screw 
positioned inside a stationary barrel at the most 
fundamental level. In the more advanced twin-screw 
systems, extrusion of materials is performed by either a 
corotating or counterrotating screw configuration. 
Irrespective of type and complexity of the function and 
process, the extruder must be capable of rotating the screw 
at a selected predetermined speed while compensating for 
the torque and shear generated from both the material being 
extruded and the screws being used.(8). However, 
regardless of the size and type of the screw inside the 
stationary barrel a typical extrusion set up consists of a 
motor which acts as a drive unit, an extrusion barrel, a 
rotating screw, and an extrusion die. A central electronic 
control unit is connected to the extrusion unit in order to 
control the process parameters such as screw speed, 
temperature, and therefore pressure. This electronic control 
unit acts as a monitoring device as well (9).The typical 
length diameter ratios (L/D) of screws positioned inside the 
stationary barrel are another important characteristic to 
consider whether the extrusion equipment is a single-screw 
or twinscrew extruder. The L/D of the screw either in a 
single-screw extruder or a twin-screw extruder typically 
ranges from 20 to 40: 1 (mm). In case of the application of 
pilot plant extruders the diameters of the screws 
significantly ranges from 18 to 30 mm. In pharmaceutical 
scale up, the production machines are much larger with 
diameters typically exceeding 50– 60mm. In addition, the 
dimensions of a screw change over the length of the barrel. 
In the most advanced processing equipment for extrusion, 
the screws could be separated by clamps or be extended in 
proportion to the length of the barrel itself. A basic single-
screw extruder consists of three discrete zones: feed zone, 
compression, and a metering zone (10). 
 
 
Figure 2: Schematic diagram of a single-screw extruder 
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Under the compression zone which is basically known as 
processing zone could be accompanied by few other steps 
such as mixing, kneading, and venting. The depth along with 
the pitch of the screw flights (both perpendicular and axial) 
differ within each zone, generating dissimilar pressures 
along the screw length (11). 
 
 
Figure 3: Screw geometry (extrusion) 
Normally the pressure within the feed zone is very low in 
order to allow for consistent feeding from the hopper and 
gentle mixing of API, polymers, and other excipients and 
therefore the screw flight depth and pitch are kept larger 
than that of other zones. At this stage of the process the 
pressure within the extruder is very low which subsequently 
gets increased in the compression zone (12). This process 
results in a gradual increase in pressure along the length of 
the compression zone, which effectively imparts a high 
degree of mixing and compression to the material (by 
decreasing the screw pitch and/or the flight depth). 
Moreover the major aim of the compression zone is not only 
to homogenize but also compress the extrudate to ensure 
the molten material reaches the final section of the barrel 
(metering zone) in a form appropriate for processing. Finally 
the final section which is known as the metering zone 
stabilizes the effervescent flow of the matrix and ensures the 
extruded product has a uniform thickness, shape, and size 
(13). A constant and steady uniform screw flight depth and 
pitch helps to maintain continuous high pressure ensuring a 
uniform delivery rate of extrudates through the extrusion 
die and hence a uniform extruded product. In addition to the 
above-mentioned systems, downstream auxiliary equipment 
for cooling, cutting, and collecting the finished product is 
also typically employed. Mass flow feeders to accurately 
meter materials into the feed hopper pelletizers, 
spheronizer, roller/calendaring device in order to produce 
continuous films, and process analytical technology such as 
near infrared (NIR) and Raman, ultrasound, and DSC 
systems are also options. Throughout the whole process, the 
temperature in all zones is normally controlled by electrical 
heating bands and monitored by thermocouples. The single-
screw extrusion system is simple and offers lots of 
advantages but still does not acquire the mixing capability of 
a twin-screw machine and therefore is not the preferred 
approach for the production of most pharmaceutical 
formulations. Moreover, a twin-screw extruder offers much 
greater versatility (process manipulation and optimisation) 
in accommodating a wider range of pharmaceutical 
formulations making this setup much more constructive. 
The rotation of the screws inside the extruder barrel may 
either be corotating (same direction) or counter-rotating 
(opposite direction), both directions being equivalent from a 
processing perspective 
 
 
Figure 4: A twin-screw extruder and screws 
A greater degree of conveying and much shorter residence 
times are achievable with an intermeshing setup. 
Furthermore, the use of reverse-conveying and forward-
conveying elements, kneading blocks, and other intricate 
designs as a means of improving or controlling the level of 
mixing required can help the configuration of the screws 
themselves to be varied. 
Ritonavir (RTV) is an antiretroviral drug and used in 
advance Human Immunodeficiency Virus (HIV). It is used as 
viral Protease Inhibitor (PI) as well as a booster for other PI 
drugs. It was first developed by AbbVie ltd in 1996, and is 
currently marketed as brand Norvir in white tablet form The 
British HIV association (BHIVA) guideline recommends the 
drug as a second line treatment for HIV, in combination with 
other antiretroviral drugs called Nucleoside and Nucleotide 
Reverse Transcriptase (NRTI). Development of viral 
resistance to the drug has been reported in clinical practice. 
Experiments have been carried out to improve the drug’s 
efficacy  
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1.5.HIV life cycle:  
The Human Immunodeficiency Virus (HIV) is a retrovirus, 
which contains a ribonucleic acid (RNA) as genetic material. 
It incorporates the RNA into the human DNA during its life 
cycle. The life cycle completes in three stages. It begins with 
the virus attaching and entering into the immune cell called 
CD4 cell. Second stage starts after entering in the CD4 cell. 
The virus gets uncoated and releases the genetic material 
into cytosol. The HIV reverse transcriptase (RT) produces 
viral DNA, which are transported to nucleus of the infected 
cell. The viral DNA is integrated to host genome by Integrase 
enzymes. In the third phase, the mRNA synthesises the 
complex of viral functional introns. They are transported out 
of the nucleus. Viral polypeptides called Gag and Pol are 
synthesized in cytosol from the introns. The viral mRNA also 
synthesises another polypeptide called Env in endoplasmic 
reticulum (ER). The Gag and Pol assemble in the cytosol and 
constitute viral core and reverse transcriptase of mature 
virus respectively. The core contains the antigenic parts such 
as protease (PR), integrase, RT and RNA. The Env makes up 
envelop of the virus. The Gag and Pol are cleaved by 
proteolysis process before conversion into mature 
functional viruses from the infected cell. 
  
 
Figure 5. Dimer and Monomer 
2.0. MATERIAL AND METHODS  
2.1.1. Materials 
Ritonavi, (Aurobindo Pharma Ltd) Copovidone, Sorbitan 
monolaurate, Dibasic calcium phosphate anhydrous, Dibasic 
calcium phosphate dihydrate, (Merck, India, RanQ 
Pharmaceuticals) Powdered cellulose, Corn starch, Mannitol, 
Silicified microcrystalline cellulose, Silicified 
microcrystalline cellulose, Microcrystalline cellulose, Sodium 
stearyl fumarate. 
 2.1.2. Film coating material  
Aquarius prime BAP 118010 white IH, Purified water USP 
(solid content 15 % w/w) 
Procedure  
Preparation of Ritonavir Immediate Release Tablets:         
Wet granulation 
 Sifting 
Sift the ritonavir USP (micronized) through ASTM ≠ 20 mesh 
1. Sift copovidone through ASTM ≠ 40 mesh. 
2. Heat the sorbitan monolaurate to 60-70° C or till it 
forms a clear transparent solution into a stainless steel 
container. 
3. Ingredients of step 1 were loaded into 3 ltr Rapid 
Mixer Granulator (RMG) and spray sorbitan mono 
laurate of step 3 slowly on this material with impellar 
at fast speed and chopper at slow speed then continue 
the mixing for 2 minutes after the complete spraying of 
sorbitan monolaurate with impellar at fast speed and 
chopper at slow speed. 
4. Unload the material of step 4 with impeller at slow 
speed and check the weight of the material. 
5. Calculate and weigh the actual quantity of material 
office step 5 required for the required for the batch. 
6. Load about 25 % w/w of sifted copovidone of step 2, 
material of step 6 and about 25% w/w of sifted 
copovidone of step 2 into Rapid mixer granulator and 
mix for 5 minutes with impeller at slow speed. 
7. Add the remaining quantity of sifted copovidone of 
step 2 to the material of step 7 and mix for 5 minutes 
with impeller at slow speed.  
8. Unload the material of step 8 with impeller at slow 
speed. 
9.  Load the material of step 9 into a feeding Hopper of 
hot melt extruder and start the melt extrusion process.  
10. Record the actual parameters observed  
11. Collect and mill the extrudes of step 10 in Multi Mill 
through 0.5 mm screen at fast speed with knives 
forward direction and collect the past extrudes.  
12. Weigh the milled extrudes of steps for 12 based on the 
yield of mild extrudes of step 12 calculate the 
quantities of the dibasic calcium phosphate, anhydrous 
dibasic calcium phosphate dehydrate, powdered 
cellulose, corn starch 400l mannitol, silicified 
microcrystalline cellulose (Prosolve SMCC® 90), 
silicified microcrystalline cellulose(Prosolv SMCC® 
50), microcrystalline cellulose and sift together 
through 40 ASTM mesh  
13. Calculate the required quantity of sodium stearyl 
fumarate based on the end of milled extrudes of step 
12 where the quantity of sodium stearyl fumarate and 
sift through ASTM ≠ 60 mesh  
14. Load the mild extrudes of step 12 and shifted material 
of a step 13 into a low shear blender and blend for 25 
minutes  
15. Add the sifted sodium lauryl stearyl fumarate of a step 
14 to the material of step 15 and blend for 5 minutes 
and unload.  
16. Compress the blend of step 16.  
17. Prepare coating suspension by dispersing Aquarius 
prime 118010 white in specified amount of purified 
water to achieve 15% w/w solid content using suitable 
stirrer. Stir the suspension for about 45 minutes 
18. Load the core tablets of step 17 in the coating pan and 
pre warm the tablets at an inlet air temperature of 50 ± 
10°C with an intermittent inching of the coating pan. 
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19. Start the spray of coating suspension of step 18 after 
the product temperature reaches 35 ± 5°C, continue 
the coating till a coat weight build up of 2.08% w/w ± 
0.50°C w/w per tablet was obtained. 
 
      2.1.3. Different composition of ritonavir immediate release tablets (14). 
TABLE-1 Formulation of ritonavir immediate release tablets 
Trial No. F1  F2 F3 F4 F5 
S.No Ingredients Qty per unit (mg) 
Intragranular (Hot melt extrusion) 
1.  
Ritonavir 
USP(micronized) 
100.00 100.00 100.00 100.00 100.00 
2.  Copovidone USNF 581.20 581.20 531.20 481.20 481.20 
3.  
Sorbitan monolaurate 
USNF 
0.00 6.80 3.4 6.80 0.00 
4.  
Dibasic calcium phosphate 
anhydrous USP 
70.00 70.00 70.00 70.00 70.00 
5.  
Dibasic calcium phosphate 
dihydrate USP 
50.00 50.00 50.00 50.00 50.00 
6.  Powdered cellulose 85.00 85.00 85.00 85.00 85.00 
7.  Corn starch USNF 93.00 93.00 93.00 93.00 93.00 
8.  Mannitol USP 85.00 85.00 85.00 85.00 85.00 
9 
Silicified microcrystalline 
cellulose (Prosolve 
SMCC®90) IH 
44.00 44.00 44.00 44.00 44.00 
10 
Silicified microcrystalline 
cellulose (Prosolve 
SMCC®50) IH 
18.00 18.00 18.00 18.00 18.00 
11 
Microcrystalline cellulose 
USNF 
114.60 114.60 114.60 114.60 114.60 
12 
Sodium stearyl fumarate 
USNF 
2.40 2.40 2.40 2.40 2.40 
Core Tablet weight 1243.20 1250.00 1196.00 1150.00 1143.20 
Film coating material 
13 
Aquarius prime BAP 
118010 white IH 
35.72 35.72 35.72 35.72 35.72 
14 
Purified water USP (solid 
content 15 % w/w) 
q.s q.s q.s q.s q.s 
Total tablet weight 1268.20 1275.00 1221.60 1175.00 1168.20 
 
2.2 EVALUATION OF TABLETS 
2.2.1. Weight Variation Test: 
To study weight variation individual weights (WI) of 20 
tablets from each formulation were noted using electronic 
balance. Their average weight (WA) was calculated. Percent 
weight variation was calculated as follows. Average weights 
of the tablets along with standard deviation values were 
calculated. 
                            % weight variation = (WA–WI) x 100/ WA 
As the total tablet weight was 655 mg, according to USP, out 
of twenty tablets ±5 % variation can be allowed for not more 
than two tablets. 
2.2.2. Hardness Test: 
10 tablets from each batch were selected and hardness was 
measured using tablet hardness tester to find the average 
tablet hardness or crushing strength. Hardness of 4 kg is 
considered suitable for handling the tablets. 
2.2.3. Tablet Thickness: 
Thickness and diameter of formulation trials were measured 
using a Digital vernier Caliper, Thickness Gauge. 10 tablets of 
each trial formulation were taken and measured individually 
at frequent intervals. 
2.2.4. Friability (%):(15). 
Friability was determined by taking 20 tablets. Tablets 
samples were weighed accurately and placed in Friabilator 
after the given specification 100 revolutions per min (4 min 
at 25 rpm). The tablets were weighed again and % friability 
was then calculated by: 
%F = x 100 
Where,         % F =  Friability of tablets in percent.  
 W  = Initial Wight of tablets. 
 W0 = Final weight of tablets. 
2.2.5. Comparison of Dissolution Profiles: 
According to US FDA guidance for dissolution data 
equivalence, model independent approach is recommended. 
This involves the use of similarity (f2) and dissimilar factor 
(f1) which provides simple means to compare the dissolution 
data. 
2.2.6. Similarity factor (f2): (16). 
The similarity factor f2 was defined as a logarithmic 
reciprocal square root transformation of the sum of squared 
error and is a measurement of the similarity in the percent 
(%) dissolution between the two curves. This was calculated 
to compare the test product and reference product with 
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respect to the drug release or dissolution profiles(17). It was 
calculated data according to the following equation: 
f2 = 50 × log {[1+ (1/n) ∑t=1 n (Rt - Tt)2]-0.5 ×100} 
Where,       n    =   number of full time points 
 Rt  =    the reference profile at the time point t 
Tt   =    the test profile at the same point t 
2.2.7. Dissimilarity factor (f1): (18). 
It is also called as Difference factor. It describes the relative 
percentage error between two dissolution profiles. The 
percent error is zero when the test and reference profiles 
are identical and increases the proportionality with the 
dissimilarity between the two profiles.  
f1 = {[∑t=1 n (Rt-Tt)] / ∑t=1 n Rt]} ×100 
2.2.8. Assay: (By HPLC) 
2.2.9. Instrumentation:  
a. High performance liquid chromatography system with 
Waters 2695 separations module/Waters E2695 separations 
module with 2489 UV- Visible detector 
b.   Data handling system (Empower pro). 
c.   Analytical column: A stainless steel column 250 mm long, 
4.6 mm internal diameter filled with Octyl silane chemically 
bonded to porous silica particles to 5µm diameter. 
 [Use Kromasil- 100 C8 5µ (250 x 4.6mm)] or Equivalent. 
3.0. RESULTS AND DISCUSSION 
The present study was undertaken to formulate ritonavir IR 
tablets. The study involves preformulation studies of drug 
and excipients, formulation and processing development 
along with evaluation of tablets made with the optimized 
formulation. Finally film coated tablets were evaluated by in 
vitro methods 
3.1. Physical Characterization of Active Pharmaceutical 
Ingredient (API) 
Table 2: Physical characterization of API 
S.No: Description Result 
1. Appearance White crystalline tan powder 
2. Solubility insoluble in water 
3. Moisture Content 2.0% L max 
 
3.2. Solubility Studies 
The solubility of ritonavir drug was studied in six different 
media. The API was found to be insoluble in water and also 
freely soluble in all the following medias. 
Table 3: Solubility Studies of ritonavir in various solvents 
Solvent pH(Approx) Solubility(mg/ml) 
0.1N HCl 1.2 171.44 
0.01N HCl 2.1 132.01 
Acetate buffer pH 4.5 4.5 48.45 
Purified water 6.5 198.26 
Phosphate buffer pH 6.8 6.8 132.45 
Phosphate buffer pH 7.2 7.2 114.33 
 
3.3. Flow Properties 
Bulk density, tapped density, carr’s index and Hausner’s 
ratio were calculated for checking the flow property of the 
API. The results of the tests are shown in the table which 
indicates that the API exhibit very poor flow as its nature is 
very fluffy. 
Table 4: Flow properties of API shown in the table 
S. No Flow properties Result 
1 Bulk density (g/ml) 0.136 ± 0.30 
2 Tapped density (g/ml) 0.253 ± 0.29 
3 Carr’s index (%) 46.26  ± 2 
4 Hausner’s ratio 1.861 ± 0.06 
 
Table 5: Drug Excipients physical compatibility studies 
S.No Ritonavir +excipients Ratio 
Initial 
Observation 
Observation after 1month  
400C/75%RH 
(open) 
400C/75%RH 
(closed ) 
2 – 80C 
closed 
1.  Ritonavir N/A White color No change in color No change in color 
No change 
in color 
2.  Ritonavir + MCC 1 : 1 White color No change in color No change in color 
No change 
in color 
3.  
Ritonavir + Lactose 
monohydrate 
1 : 1 White color No change in color No change in color 
No change 
in color 
4.  Ritonavir + HPMC 1 : 1 White color No change in color No change in color 
No change 
in color 
5.  
Ritonavir + Ethyl 
Cellulose 
1 : 1 White color No change in color No change in color 
No change 
in color 
6.  Ritonavir + Aerosil 1 : 1 White color No change in color No change in color 
No change 
in color 
7.  
Ritonavir + Magnesium 
stearate 
1 : 1 White color No change in color No change in color 
No change 
in color 
 
3.4.Precompression Studies 
Bulk density, tapped density, compressibility index and 
hausner’s ratio test was performed. The prepared blends of 
various formulations showed bulk density in the range of 
0.30 to 0.51, which indicates the flow of blends are fair to 
good; tapped density in the range of 0.42 to 0.71 g/ml 
respectively, which indicates that there is good flow. The % 
compressibility index range was found to be 24 to 33%, 
which indicates the flow is poor and passable of the blends 
and Hausner’s ratio in the range of 1.32 to 1.50, Hausner’s 
ratio indicates the flow is poor. 
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3.5.The limits of the entire test indicate that the blend flow was poor. 
Table 6 Precompression data 
S.No Formula 
Bulk 
density(g/ml) 
Tapped density 
(g/ml) 
Compressibility 
index (%) 
Hausner’s ratio 
1 F1 0.595 0.735 19.05 1.235 
2 F2 0.581 0.757 23.27 1.303 
3 F3 0.581 0.735 20.93 1.265 
4 F4 0.581 0.781 25.58 1.344 
5 F5 0.555 0.735 24.44 1.323 
 
3.6. Post compression Studies 
Ten tablets of each formulation (core and coated) are 
selected randomly and average weight was determined. 
Then individual tablet is weighed and compared with an 
average weight. The USP limit of % allowed variation of 
tablets above 400mg is ± 5%. The % weight variations of the 
formulations mentioned in above table are within the limit. 
The values mentioned in above table for hardness test are 
within the limit and matching the innovator products 
Thickness of all the formulations was found in the range for 
core tablets 5.75 to 6.06 mm. and coated tablets for 6.09-
6.67 Friability is the ability to withstand the abrasion during 
transporting. The friability limit according to USP is 0.5 to 1 
%. The values mentioned for all the tests are within the limit. 
 
Table 7: Evaluation parameters of core tablets are shown in the table 
S.No Formula 
Thickness (mm) Avg 
of 10 tablets 
Hardness (KP) Avg 
of 10 tablets 
Friability (%w/w) 
1.  F1 7.83-7.91 22.2-26.5 Nil 
2.  F2 7.82-7.91 22.7-26.9 Nil 
3.  F3 7.53-7.67 21.5-26.5 Nil 
4.  F4 7.18-7.25 23.5-27.8 Nil 
5.  F5 7.09-7.22 23.3-27.2 Nil 
 
3.7. DISSOLUTION STUDIES 
The dissolution was carried out for different formulation trials and also for the innovator. The various results that are obtained 
are tabulated below. 
Table 8: In vitro drug release data of innovator 
Time (mins) % Drug Release 
10 42.49±0.62 
20 60.98±0.78 
30 71.29±0.98 
45 78.12±0.79 
60 83.62±0.21 
90 87.21±0.74 
120 91.22±1.09 
 
Table 9: Comparison of Drug release of Reference, Formulation 5 and Stability loaded Formulation 5 
Time 
(mins) 
% Drug Release 
(innovator) 
F1 F2 F3 F4 F5 
10 14 15 14 20 19 24 
20 35 34 32 42 39 45 
30 52 51 49 60 58 65 
45 72 71 69 81 81 83 
60 86 85 85 92 91 93 
90 94 98 99 97 100 99 
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Figure 6: Comparison of Dissolution profile of ritonavir formulations Vs Innovator 
3.8. Stability Data of formulation F5 
Dissolution of trial F-5 tablets was comparable with 
marketed product. So tablets of this batch were kept for 
stability studies. The results of stability studies are shown in 
Table after 3 months the physical parameters of the tablets 
were same. Water content and related substance are within 
limits. The tablets were tested for Physical appearance, 
assay, relative substances, dissolution, moisture content at 
initial, 1st month, 2nd month and 3rd month in accelerated 
conditions (40+20C & 75+5%RH). 
 
Table 10. Stability study data (accelerated) of Formulation – 5: 
S.no Parameters Specifications 
Test Condition 
(Accelerated) 
40 ± 20C & 75 ± 5% RH 
0 Day 1M Month 2M month 3M Month 
1 Description 
Immediate release 
coated tablet. 
Comply Comply Comply Comply 
2 Moisture content Not more than 2.0% 1.427% 1.326% 1.211% 1.143 
3 Assay 
NLS 90% &NMT 
110%of labeled 
amount of drug. 
 
 
100.9% 
99.2% 99.3% 99.5% 
4 
Related 
substances 
by HPLC 
 
Impurity A&B NMT 0.5% 0.02 0.04 0.03 0.04 
Impurity a,b,c,d NMT 2.3% 0.60 0.69% 0.058% 0.68% 
unidentified 
impurity 
NMT 0.13% 0.06% 0.08% 0.09% 0.10% 
Total impurity NMT 1.6% 1.01 1.25 1.39 1.55 
 
Stability studies for the optimized tablets were carried out at 
a temperature and relative humidity of 40ºC/ 75% ± 5% RH 
for a period of three months. Tablets are evaluated for 
physical appearance, color, moisture content, assay, related 
substances and dissolution studies. An average drug content 
of the tablets 97.625% w/w. Tablets have not shown any 
significant change during storage. Hence, it was concluded 
that the optimized tablets have good stability during their 
shelf life. 
Formulation -5 Stability sample withdrawn 400C/75%RH 
three months % drug releasing time profile comparing initial 
product with marketed product. 
 
Table 11: Stability sample with drawl 400C/75%RH three months % drug releasing time profile 
S.no Time (min) Marketed product% 
drug release 
Initial for formulation-5 
%drug release 
400C/75%RH(F5) 
% drug release 
1 0 0 0 0 
2 10 10.08 ± 2.02 9 ± 2 9 ± 3 
3 20 22.21 ± 4.0 22 ± 2 22 ± 4 
4 30 42.30 ± 2.0 42 ± 2 42 ± 2 
5 45 55.40 ± 2.45 57 ± 1 56 ± 3 
6 60 75.32 ± 3.0 72 ± 3 72 ± 2 
7 90 89.65 ± 2.02 87 ± 2 86 ± 5 
8 120 96.32 ± 2.0 92 ± 2 91 ± 4 
9 150 98.32 ± 1.5 96 ± 1 95 ± 2 
10 180 99.01 ± 4.0 98 ± 5 97 ± 6 
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4.0. CONCLUSION  
The present work was carried out to formulate and evaluate 
Ritonavir immediate release tablets.The drug excipient 
compatibility studies were carried out by HPLC. Based on 
the results, it was confirmed that there is no interaction 
between drug and excipient at different conditions. Eight 
formulation trails of Ritonavir tablets were conducted using 
different polymers at different concentrations. Physical 
characterizations of marketed product API and solubility 
studies Flow properties of API were studied and it was 
confirmed that Ritonavir exhibits very poor flow properties 
Blends of all formulations were prepared and pre 
compression properties were studied. The results indicated 
that all the formulation blends exhibited good flow 
properties, Formulations were compressed by hot melt 
extrusion method and subjected to post compression 
studies. For core tablets and coated tablets respectively. The 
results were found to be within the limits. 
In vitro drug release of all formulations was carried out in 
dissolution medium 900 ml purified water and in 
multimedia buffer by using USP type – II (paddle). Figure 6 
showing dissolution profile of different formulations of 
ritonavir immediate release tablets. Among formulations 
developed by wet granulation method F5 shows highest % 
drug release (99 %) at 120 mins The optimized formulation 
was subjected to accelerated stability studies  at a 
temperature and relative humidity of 40 C  75%   5%  H 
for a period of three months. Tablets are evaluated for 
physical appearance, color, moisture content, assay, related 
substances and dissolution studies.  
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